Sign Up to like & get
recommendations!
0
Published in 2020 at "Neuropsychopharmacology"
DOI: 10.1038/s41386-020-00911-5
Abstract: The remarkably high and growing placebo response rates in clinical trials for CNS indications, such as depression and schizophrenia, constitute a major challenge for the drug development enterprise. Despite extensive literature on participant expectancies and…
read more here.
Keywords:
participant focused;
response;
placebo response;
major depressive ... See more keywords